Inovio Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Inovio Pharmaceuticals' es Jacqueline Shea , nombrado en May 2022, tiene una permanencia de 2.08 años. compensación anual total es $2.44M, compuesta por 30.8% salario y 69.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.13% de las acciones de la empresa, por valor de $300.81K. La antigüedad media del equipo directivo y de la junta directiva es de 3.7 años y 5.6 años, respectivamente.
Información clave
Jacqueline Shea
Chief Executive Officer (CEO)
US$2.4m
Compensación total
| Porcentaje del salario del CEO | 30.8% |
| Permanencia del CEO | 2.1yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 3.7yrs |
| Promedio de permanencia en la Junta Directiva | 5.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates
May 15
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates
May 13Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?
Oct 23Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug
Oct 13Inovio Pharmaceuticals: Long On Promise, Short On Results
Sep 27Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M
Aug 09Inovio: After All These Years
Jul 19Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022
Apr 15Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?
Mar 21Inovio Undervalued On Potential 2022 Catalyst
Jan 26Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Dec 31Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side
Nov 18Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Sep 24Inovio: Simply Cannot Be Ignored
Sep 03Inovio Has 4 Sources Of Potential Value
Jun 23Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt
Jun 11Inovio stock trades higher defying insider sale
Jun 07Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$125m |
| Dec 31 2023 | US$2m | US$751k | -US$135m |
| Sep 30 2023 | n/a | n/a | -US$165m |
| Jun 30 2023 | n/a | n/a | -US$168m |
| Mar 31 2023 | n/a | n/a | -US$241m |
| Dec 31 2022 | US$4m | US$730k | -US$280m |
| Sep 30 2022 | n/a | n/a | -US$332m |
| Jun 30 2022 | n/a | n/a | -US$355m |
| Mar 31 2022 | n/a | n/a | -US$328m |
| Dec 31 2021 | US$2m | US$468k | -US$304m |
| Sep 30 2021 | n/a | n/a | -US$221m |
| Jun 30 2021 | n/a | n/a | -US$142m |
| Mar 31 2021 | n/a | n/a | -US$188m |
| Dec 31 2020 | US$2m | US$431k | -US$166m |
| Sep 30 2020 | n/a | n/a | -US$180m |
| Jun 30 2020 | n/a | n/a | -US$222m |
| Mar 31 2020 | n/a | n/a | -US$123m |
| Dec 31 2019 | US$1m | US$335k | -US$119m |
Compensación vs. Mercado: La compensación total de Jacqueline($USD2.44M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.62M).
Compensación vs. Ingresos: La compensación de Jacqueline ha sido consistente con los resultados de la empresa en el último año.
CEO
Jacqueline Shea (58 yo)
2.1yrs
Permanencia
US$2,438,908
Compensación
Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 2.1yrs | US$2.44m | 0.13% $ 271.5k | |
| Chief Financial Officer | 22yrs | US$1.16m | 0.095% $ 199.7k | |
| Chief Scientific Officer | 5.3yrs | US$1.14m | 0.094% $ 196.4k | |
| Manager of Investor Relations | no data | sin datos | sin datos | |
| General Counsel & Chief Compliance Officer | 2.6yrs | sin datos | sin datos | |
| Senior Vice President of Quality Assurance | no data | sin datos | sin datos | |
| Senior Vice President of Clinical Development | 3.7yrs | sin datos | sin datos | |
| Senior Vice President of Biological Manufacturing & Clinical Supply Management | 3.7yrs | sin datos | sin datos | |
| Senior Vice President of Engineering Development | no data | sin datos | sin datos | |
| Senior Vice President of Business Development | 3.4yrs | sin datos | sin datos | |
| Chief Commercial Officer | 3.7yrs | sin datos | sin datos | |
| Senior Vice President of Early-Stage Clinical Development | less than a year | sin datos | sin datos |
3.7yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de INO se considera experimentado (3.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 2.1yrs | US$2.44m | 0.13% $ 271.5k | |
| Independent Director | 6.5yrs | US$123.69k | 0.032% $ 67.4k | |
| Independent Director | 5.4yrs | US$118.69k | 0.025% $ 52.9k | |
| Independent Director | 4.4yrs | US$119.31k | 0.027% $ 56.8k | |
| Independent Chairman of Board of Directors | 20.5yrs | US$151.19k | 0.039% $ 80.9k | |
| Chairman of the Scientific Advisory Board & Director | 24.4yrs | US$201.79k | 0.32% $ 665.9k | |
| Member of Scientific Advisory Board | 15yrs | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$126.94k | 0.030% $ 62.2k | |
| Member of Scientific Advisory Board | 12.3yrs | sin datos | sin datos | |
| Independent Director | 3.1yrs | US$108.69k | 0.026% $ 54.5k | |
| Member of Scientific Advisory Board | 5.6yrs | sin datos | sin datos |
5.6yrs
Permanencia media
68yo
Promedio de edad
Junta con experiencia: La junta directiva de INO se considera experimentada (5.6 años de antigüedad promedio).